Novo Nordisk AS (NVO.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec30

Seeking Alpha publishes analysis suggesting oral Wegovy will pressure margins, recommends "Sell" for Novo Nordisk stock.

14:33

Analysis indicates Novo Nordisk's GLP-1 weight-loss drugs may offer additional health benefits.

13:40

Novo Nordisk and Eli Lilly lower prices of their weight-loss drugs in China

13:01

Novo Nordisk announces next dividend with an ex-date of March 31, 2026

10:42

US Government Announces New Payment Model to Lower Costs of GLP-1 Drugs

03:40

Investment firm Cwm LLC increases its stake in Novo Nordisk by 35%

00:00

Schedules & Filings

Schedules

Filings

Feb4

Earning Release(EST)

FY2025 Annual Earning Release

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 11.78 B, Net Income 3.143 B, EPS 0.707

Novo Nordisk A/S (NVO.US) Q3 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q3 2025 Earnings Conference Call

Aug26

Distribution Plan(EST)

Cash dividend 0.5843 USD

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More